“ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The next wave of incretin therapies unveiled in New Orleans”, d, vol. 4, no. 23, pp. 46–47, Jul. 2026, Accessed: Jul. 29, 2026. [Online]. Available: https://thediabzen.com/index.php/d/article/view/66